Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia
NCT00360776 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2017-04-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FNTA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-07-31Results posted on the registry: Boston Children's Hospital, Lonafarnib + Zoledronic Acid (NCT00879034)
- 2017-05-24Results posted on the registry: Monica E. Kleinman, Lonafarnib (NCT00425607)
- 2016-08-31Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Lonafarnib (NCT01495585)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision